|Bid||11.11 x 1400|
|Ask||11.34 x 900|
|Day's Range||10.67 - 11.34|
|52 Week Range||2.75 - 16.47|
|Beta (3Y Monthly)||4.63|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 9, 2017 - Aug 14, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.75|
Zynerba Pharmaceuticals, Inc.'s (NASDAQ:ZYNE): Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty...
Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the publication of data from the Phase 2 FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) clinical trial. This trial evaluated ZYN002 cannabidiol (CBD) gel in pediatric and adolescent patients with Fragile X syndrome (FXS). “Fragile X is a family diagnosis, impacting not only the diagnosed child but also the entire family unit,” said Honey Heussler, MBBS, FRACP, MRCPCH, PGCAP, DM, Associate Professor, University of Queensland and Medical Director Child Development, Children’s Health Queensland, and an investigator in the FAB-C study.
DEVON, Pa., Aug. 06, 2019 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and.
Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the Canaccord Genuity 39th Annual Growth Conference. The presentation will take place on Wednesday August 7, 2019 at 5:00PM EDT at the InterContinental Hotel in Boston, Massachusetts. A live webcast of the presentation will be accessible on the Investor Relations page of http://www.zynerba.com.
The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges. Learn about the marijuana stocks on the Nasdaq.
Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to be on the higher side in the second quarter due to clinical studies on its lead pipeline candidate, Zygel.
Jim Cramer is wary of Zynerba Pharmaceuticals . "No. If you want this, you want GW Pharmaceuticals ," said Cramer to a caller during the Lightning Round of his "Mad Money" program on Monday. In this daily bar chart of ZYNE, below, we can see that prices quietly bottomed around $3 in late December.
On Monday's “Mad Money,” Jim Cramer said he remains bearish on Range Resources Corp. (NYSE: RRC ) saying natural gas is the weakest part of the petrol chain. Cramer says although it's speculative, he is ...
In the latest trading session, Zynerba Pharmaceuticals (ZYNE) closed at $11.87, marking a +1.63% move from the previous day.
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you buy shares in a...
Medicare for all may not be just a Democratic talking point as the 2020 campaign kicks into high gear. It could also “dramatically” increase access to medical marijuana, according to Nicholas Vita, CEO of cannabis company Columbia Care.
Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the Company will be added as a member of the U.S. all-cap Russell 3000® and small-cap Russell 2000® Indexes at the conclusion of the 2019 Russell indexes annual reconstitution. The annual reconstitution will conclude and the newly reconstituted indexes will begin running at the open of the U.S. markets today, July 1, 2019. Annual Russell indexes reconstitution captures the 4,000 largest U.S. stocks as of May 10, ranking them by total market capitalization. Membership in the Russell 3000 Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000 Index as well as the appropriate growth and value style indexes.
Investors continue to show interest in the medical possibilities of cannabis-derived cannabidiol, or CBD, eagerly watching Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ) as it begins patient trials on a CBD-infused ...
Zynerba Pharmaceuticals (ZYNE) closed at $12.48 in the latest trading session, marking a -0.56% move from the prior day.